ASCO/EHA/ICML 2023 Look-back: CAR-T Remains King in DLBCL and MM

Impressive data from Yescarta and Carvykti set both CAR-T therapies up to extend leadership in DLBCL and MM, respectively

Executive Summary

Multiple CAR-T data sets were presented at the summer oncology conference series, confirming the long-term potential of CAR-T as a primary treatment modality in heme malignancies. P3 data from Yescarta (axi-cel; GILD) and Carvykti (cilta-cel; JNJ, LEGN) in earlier lines of therapy in DLBCL and MM, respectively, demonstrated major improvements in survival endpoints and will help cement CAR-T as SoC in these settings and GILD, JNJ/LEGN as market leaders in their particular spaces. GILD’s CD19 CAR-T franchise appears poised to usurp Roche’s CD20 mAb franchise in NHL, while JNJ continues to be well positioned to become the market leader in MM, pushing aside BMS.